2024
Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma
Schoenfeld D, Djureinovic D, Su D, Zhang L, Lu B, Kamga L, Mann J, Huck J, Hurwitz M, Braun D, Jilaveanu L, Ring A, Kluger H. Decoy-resistant IL-18 reshapes the tumor microenvironment and enhances rejection by anti-CTLA-4 in renal cell carcinoma. JCI Insight 2024 PMID: 39561007, DOI: 10.1172/jci.insight.184545.Peer-Reviewed Original ResearchAnti-CTLA-4Renal cell carcinomaIL-18IL-18BPCell carcinomaTumor microenvironmentTumor typesPatients treated with immune checkpoint inhibitorsRegulatory T cell levelsAnti-PD-1 treatmentCD8+ T cellsAnti-PD-1Immune checkpoint inhibitorsCell renal cell carcinomaNon-responder patientsMyeloid cell populationsT cell levelsCytokine interleukin-18Anti-cancer efficacySecreted binding proteinCheckpoint inhibitorsResponding patientsPreclinical modelsT cellsMurine model
2023
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma
Huang R, Chen Z, Kroeger N, Pantuck A, Said J, Kluger H, Shuch B, Ye H. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer 2023, 22: 347-353. PMID: 38195301, DOI: 10.1016/j.clgc.2023.12.003.Peer-Reviewed Original ResearchRenal cell carcinomaClear cell renal cell carcinomaCell renal cell carcinomaMetastatic clear cell renal cell carcinomaMetastatic renal cell carcinomaCell carcinomaClear cell carcinomaCD70 expressionMetastatic tumorsRenal tumorsTherapeutic targetAdvanced renal cell carcinomaMetastatic clear cell carcinomaCancer-specific survivalPapillary renal cell carcinomaExpression of CD70Normal renal parenchymaPrimary renal tumorsPrimary tumor tissuesPromising therapeutic targetPotential therapeutic targetHypoxia pathway proteinsHypoxia-inducible factorSarcomatoid differentiationNormal human tissues
2017
Microvessel density as a prognostic marker in high-risk renal cell carcinoma.
Weiss S, Puligandla M, Jilaveanu L, Haas N, Wang X, Zito C, Boeke M, Neumeister V, Manola J, DiPaola R, Kluger H. Microvessel density as a prognostic marker in high-risk renal cell carcinoma. Journal Of Clinical Oncology 2017, 35: 4565-4565. DOI: 10.1200/jco.2017.35.15_suppl.4565.Peer-Reviewed Original ResearchHigher microvessel densityRenal cell carcinomaDisease-free survivalHigh-risk renal cell carcinomaOverall survivalMicrovessel densityTreatment armsEntire cohortCell carcinomaNephrectomy specimensGrade I/IIVascular endothelial growth factor (VEGF) pathwayStratified log-rank testEndothelial growth factor pathwayClear cell renal cell carcinomaImproved overall survivalCell renal cell carcinomaClear cell histologyShorter overall survivalLog-rank testTumor microvessel densityAbsence of necrosisGrowth factor pathwaysAdjuvant sunitinibImproved OS
2016
MET Inhibition in Clear Cell Renal Cell Carcinoma
Xie Z, Lee YH, Boeke M, Jilaveanu LB, Liu Z, Bottaro DP, Kluger HM, Shuch B. MET Inhibition in Clear Cell Renal Cell Carcinoma. Journal Of Cancer 2016, 7: 1205-1214. PMID: 27390595, PMCID: PMC4934028, DOI: 10.7150/jca.14604.Peer-Reviewed Original ResearchClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaCell carcinomaMET pathwayVEGFR2 inhibitorSmall molecule VEGFR inhibitorsOncogenic alterationsVEGFR tyrosine kinase inhibitorsDirect anti-tumor effectEffect of cabozantinibWorse overall survivalCancer Genome Atlas (TCGA) datasetPotential anti-tumor activityAnti-tumor effectsLimited preclinical dataTyrosine kinase inhibitorsAnti-angiogenic effectsAnti-tumor activitySoft agar colony formationCcRCC cell linesCell viabilityMet/HGFAgar colony formationOverall survivalGenomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-2175. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellCell DedifferentiationDNA Mismatch RepairDNA-Binding ProteinsExomeFemaleGenes, p53HumansKidney NeoplasmsLoss of HeterozygosityMaleMiddle AgedMutationNuclear ProteinsOncogenesPolymorphism, Single NucleotidePrognosisTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseConceptsClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSarcomatoid elementsCarcinomatous elementsCell carcinomaSomatic single nucleotide variantsVon Hippel-Lindau tumor suppressorPoor-prognosis cancerTreatment of patientsTumor protein p53 (TP53) mutationsMismatch repair deficiencyRich interaction domain 1ASarcomatoid featuresPoor prognosisUnknown pathogenesisPolybromo-1TP53 mutationsP53 mutationsSarcomatoid transformationPan-cancer genesExome sequencingTumorsRepair deficiencyProtein 1Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.
Bi X, Zhao S, Adeniran A, Kluger H, Xie Z, Nawaf C, Merino M, Valera V, Pantuck A, Said J, Belldegrun A, Lifton R, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Journal Of Clinical Oncology 2016, 34: 509-509. DOI: 10.1200/jco.2016.34.2_suppl.509.Peer-Reviewed Original ResearchDriver genesCancer driver genesSomatic mutationsProtein traffickingIllumina sequencingSomatic cellsGenomic characterizationCell differentiationCell adhesionLoss of heterozygosityClear cell renal cell carcinomaGenesMutational signaturesCell renal cell carcinomaClonal divergenceGenetic alterationsMutationsTP53 mutationsRepair deficiencySarcomatoid transformationSubset of tumorsCcRCCHypermutationRenal cell carcinomaBAP1
2015
MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors
Shuch B, Falbo R, Parisi F, Adeniran A, Kluger Y, Kluger HM, Jilaveanu LB. MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors. BioMed Research International 2015, 2015: 192406. PMID: 26448928, PMCID: PMC4584049, DOI: 10.1155/2015/192406.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaCell renal cell carcinomaMetastatic sitesRenal cell carcinomaMET expressionCell carcinomaPredictive biomarkersPrimary tumorMetastatic clear cell renal cell carcinomaMetastatic kidney cancerAppropriate patient selectionDistant metastatic sitesPatient selectionMetastatic tissuesKidney cancerMET pathwayTissue microarrayBiomarker assessmentNumber of casesPrimary siteModerate concordancePathway inhibitorTumorsDistant tissuesNephrectomy
2014
PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma?
Barr ML, Jilaveanu LB, Camp RL, Adeniran AJ, Kluger HM, Shuch B. PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma? Journal Of Clinical Pathology 2014, 68: 12. PMID: 25315900, PMCID: PMC4429054, DOI: 10.1136/jclinpath-2014-202259.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaPAX-8 expressionMetastatic renal cell carcinomaRenal tumorsMetastatic sitesCell carcinomaClear cell renal cell carcinomaPAX-8 stainingCell renal cell carcinomaPAX-8Distant sitesNormal renal tissueUseful diagnostic markerAdjacent normal kidneyHistological typePrimary tumorDistant tumorsLack of expressionRenal originImmunohistochemical stainsChromophobe tumorsClear cellsRenal tissueNormal kidneyTissue microarrayNY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
Giesen E, Jilaveanu LB, Parisi F, Kluger Y, Camp RL, Kluger HM. NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma. Oncotarget 2014, 5: 5209-5217. PMID: 24970819, PMCID: PMC4170640, DOI: 10.18632/oncotarget.2101.Peer-Reviewed Original ResearchConceptsNY-ESO-1 expressionNY-ESO-1Renal cell carcinomaCell carcinomaMetastatic sitesRenal tissueCancer-testis antigen NY-ESO-1Antigen NY-ESO-1Adjacent normal renal tissuesClear cell renal cell carcinomaRCC specimensMetastatic RCC specimensPapillary renal cell carcinomaCell renal cell carcinomaPotential immunotherapeutic targetAdoptive cell therapySubset of RCCTumor-specific antigensClear cell carcinomaNovel immune therapiesPrimary RCC specimensBenign renal tissueNormal renal tissueDifferent tumor sitesImmune therapyPD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases. Journal Of Cancer 2014, 5: 166-172. PMID: 24563671, PMCID: PMC3931264, DOI: 10.7150/jca.8167.Peer-Reviewed Original ResearchPD-L1 expressionMetastatic sitesPD-L1Tissue microarrayMetastatic specimensTumor PD-L1 expressionClear cell renal cell carcinomaPD-1 inhibitorsAutomated Quantitative AnalysisMetastatic RCC patientsCell renal cell carcinomaSite of metastasisRenal cell carcinomaClear cell RCCRenal cell carcinoma cellsInter-tumor heterogeneityRCC patientsCell carcinomaNephrectomy specimensTumor expressionCore biopsyImmune escapeCell RCCBiopsy coresClinical development
2012
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
Gibney GT, Aziz SA, Camp RL, Conrad P, Schwartz BE, Chen CR, Kelly WK, Kluger HM. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Annals Of Oncology 2012, 24: 343-349. PMID: 23022995, PMCID: PMC3551486, DOI: 10.1093/annonc/mds463.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorCarcinoma, Renal CellCell Line, TumorCell ProliferationFemaleHepatocyte Growth FactorHumansIndolesKidney NeoplasmsMaleMiddle AgedPiperazinesPrognosisProto-Oncogene Proteins c-metPyrrolidinonesQuinolinesSulfonamidesTissue Array AnalysisConceptsRenal cell carcinomaClear cell renal cell carcinomaC-Met expressionCell renal cell carcinomaHigh c-Met expressionAdjacent normal renal tissuesNormal renal tissueARQ 197Cell carcinomaRenal tissueRCC tumorsTissue microarrayWorse disease-specific survivalC-MetClear cell RCC cell linesC-Met protein expressionCell linesPoor pathologic featuresCell subset analysisDisease-specific survivalPapillary renal cell carcinomaRange of malignanciesC-Met pathwayC-Met inhibitionPotential therapeutic target